Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience-Reference-Cited by-同舟云学术

Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience

Published:2022-05-02 Issue:7 Volume:97 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Mohan Meera¹^ORCID,Becnel Melody Renee²,Shah Urvi A.³,Dong Huaying¹,Gundarlapalli Sravani⁴,Peterson Timothy⁵,Orozco Jennifer S.⁵,Horowitz Sandra²,Chhabra Saurabh¹^ORCID,Dhakal Binod¹^ORCID,Thanendrarajan Sharmilan⁴^ORCID,Radhakrishnan Sabarinath Venniyil¹,Al Hadidi Samer⁴^ORCID,Tan Carlyn³^ORCID,Mailankody Sham³,Hultcrantz Malin³,Korde Neha³^ORCID,Hassoun Hani³,Lesokhin Alexander M.³,Thomas Sheeba K.²,Patel Krina K.²,Manasanch Elisabet E.²^ORCID,Weber Donna M.²,Szabo Aniko¹,Kaufman Gregory P.²,Lee Hans C.²^ORCID,Zangari Maurizio⁴^ORCID,van Rhee Frits⁴^ORCID,Usmani Saad Z.³,D'Souza Anita¹^ORCID,Orlowski Robert Z.²,Schinke Carolina⁴^ORCID

Affiliation:

1. Medical College of Wisconsin, Froedtert Clinical Cancer Center Division of Hematology/Oncology Milwaukee Wisconsin USA

2. The University of Texas MD Anderson Cancer Center Department of Lymphoma & Myeloma Houston Texas USA

3. Myeloma Service, Department of Medicine Memorial Sloan Kettering Cancer Center New York New York USA

4. Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences Little Rock Arkansas USA

5. Janssen Pharmaceuticals Beerse Belgium

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26580

Reference13 articles.

1. The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma

2. The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

3. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

4. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

5. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD46–ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts;Cancers;2023-11-09

2. CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies;Blood Advances;2023-10-25

3. Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg;Hematology;2023-03-07

4. How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma;Cancers;2022-12-27